Modality
Peptide
MOA
RAS(ON)i
Target
KRASG12D
Pathway
Tau
TTR Amyloidosis
Development Pipeline
Preclinical
~May 2020
→ ~Aug 2021
Phase 1
Nov 2021
→ Sep 2031
Phase 1Current
NCT04178598
910 pts·TTR Amyloidosis
2021-11→2031-09·Completed
910 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-09-175.5y awayPh2 Data· TTR Amyloidosis
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Complet…
Catalysts
Ph2 Data
2031-09-17 · 5.5y away
TTR Amyloidosis
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04178598 | Phase 1/2 | TTR Amyloidosis | Completed | 910 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR |